Sagent Pharmaceuticals and Chongqing Lummy Pharmaceutical Company Announce Development Collaboration

Sagent Pharmaceuticals, Inc. today announced a development collaboration agreement with Chongqing Lummy Pharmaceutical Company (300006:CH). Details of the agreement are confidential."Chongqing Lummy is a well established company with more than 90 marketed injectable products in China," said Jeffrey M. Yordon, chief executive officer, founder, and chairman of the board of Sagent. "They have an established development capability and we look forward to a successful collaboration and our continued growth in regulated markets as well as the Chinese domestic market.""We are pleased to be working with a partner that has a strong position in the U.S. specialty injectable market," said Qiu Yu, chairman and president Chongqing Lummy Pharmaceutical Company. "Sagent's experienced sales organization as well as its marketing and distribution capabilities will provide us the opportunity to enter the U.S. market."